Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES HELLMAN & FRIEDMAN IN CONNECTION WITH THE ACQUISITION OF BAIN CAPITAL’S STAKE IN SECURITAS DIRECT VERISURE GROUP
Mandate

VINGE ADVISES HELLMAN & FRIEDMAN IN CONNECTION WITH THE ACQUISITION OF BAIN CAPITAL’S STAKE IN SECURITAS DIRECT VERISURE GROUP

October 05, 2015

Vinge and Latham & Watkins LLP have advised Hellman & Friedman in connection with the acquisition of Bain Capital’s stake in Securitas Direct Verisure Group. Verisure Securitas Direct is a leading supplier of professionally monitored home alarms, fire alarms and connected services for homes and businesses. The company’s 1.8 million customers are spread over 13 countries in Europe and South America. The transaction is subject to customary regulatory conditions and approvals.

Vinge’s team consisted of partner Jonas Bergström together with, among others, associates Linda Sengul and Carl Sander. Partner Louise Brorsson Salomon and associates Anders Morén and Linn Adelwald provided financing advice in relation to the transaction.

Related

Vinge advises Irisity in connection with issue of units

 Vinge advises Irisity AB (publ) in connection with its rights issue of units consisting of shares and warrants. The issue is guaranteed to 80 per cent through subscription commitments and external guarantors.
October 03, 2024

Vinge has advised the municipality of Varberg in legal proceedings regarding a detailed development plan for a new residential area

 The detailed development plan for approximately 50 new homes in Trönningenäs, north of the city of Varberg, was adopted by the municipality on 23 February 2023. It was subsequently appealed in several stages. By decision of the Land and Environment Court of Appeal, the plan become legally binding on 2 October 2024.
October 03, 2024

Vinge has advised Egetis Therapeutics in connection with directed share issuances

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with directed share issuances whereby Egetis Therapeutics receives gross proceeds of SEK 300 million.
October 03, 2024